Quantum Biopharma Ltd. Class B Subordinate Voting SharesQNTM
Market Cap: $6.3M
About: Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
Employees: 8
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
25% more funds holding
Funds holding: 12 [Q1] → 15 (+3) [Q2]
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
67% less capital invested
Capital invested by funds: $476K [Q1] → $159K (-$316K) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for QNTM.
Financial journalist opinion
Based on 6 articles about QNTM published over the past 30 days